What is the role of antiplatelet aggregation therapy in the treatment of necrobiosis lipoidica?

Updated: Mar 06, 2020
  • Author: Cheryl J Barnes, MD; Chief Editor: George T Griffing, MD  more...
  • Print

Antiplatelet aggregation therapy with aspirin and dipyridamole has been tried owing to a belief that necrobiosis lipoidica results from platelet-mediated vascular occlusion or immune mechanisms that alter platelet survival. [7] These drugs are thought to prolong platelet survival time and, hence, prevent further worsening of necrobiosis lipoidica. The results of double-blind studies with aspirin and dipyridamole have varied but overall have shown some beneficial effects from the therapy.

Littler and Tschen reported a case of necrobiosis lipoidica that was treated successfully with pentoxifylline, a drug used in the treatment of intermittent claudication. [30] Pentoxifylline not only inhibits platelet aggregation but is also believed to decrease blood viscosity by increasing fibrinolysis and red blood cell deformity.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!